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IMMUNOLOGICAL responses appear to be
involved in limiting the extent of some
human tumours, and stimulation of this
immune response is currently being investi-
(fated as a treatment for cancer, both as
adjuvant therapy following radical surgery
and in advanced disease. Levamisole,
Bacille Calmette-Guerin and Coryne-
bacterium parvum are all known to stimu-
late various components of the immune
response, and C. parrum given i.v. inhibits
primary tumour growth and metastasis
formation in experimental animal tumours
(Castro, 1977). The level of immunity is
heightened by this treatment, as demon-
strated by delayed hypersensitivity testing
(Israel et al., 1-975). However, i.v. injection
of bacteria and bacterial products also
activat,es blood coagulation and fibrino-
lysis (Sherry et al., 1959a, b) and there is
evidence that tumour growth and implant-
ation of cancer cells may be impeded by
anticoacgulation or activation of fibrino-
lysis (Peterson, 1968; Rudenstam, 1968;
Brown, 1973).
Patients who have had a radical removal
of a carcinoma of the colon or rectum in
this hospital, and without evidence of
metastases, are randomized within a con-
trolled clinical trial to receive adjuvant
immunotherapy with i.v. C. parrum. The
immune function of these patients is
closely monitored, and they are followed
up regularly to determine the onset of
metastatic disease. However, in view of
the possible importance of changes in
coagulation and fibrinolysis as well as
immune stimulation in the therapeutic
effects of C. parvum, we have taken the
opportunity to investigate the acute
changes in coagulation and fibrinolysis
that occur during and immediately after
the infusion of C. parrum.
Five patients ranging in age from 59-72
years were studied before, during and
immediately after a single infusion of C.
parvurn (Burroughs Wellcome) 5 mg/M2
body surface area. All the patients had
received at least 2 previous identical infu-
sions. The formalin-killed organism was
given in 100 ml of 09%o NaCl over a
period of 30 min. Blood samples were
taken for analysis immediately before and
then about 20, 80, 140 and 250 min after
the start of the infusion. Changes in
pulse, temperature and blood pressure
were also measured at 15 min intervals.
Venous blood samples were drawn with
minimal or no venous occlusion through a
butterfly needle inserted in the opposite
arm to that used for injection of the
organism. The first few ml of blood were
discarded, and then 7 ml was drawn into a
polystyrene syringe for 3-thromboglobul.in
estimation (Radiochemical Centre, Amer-
sham). Blood for the remaining tests was
drawn into a polypropylene syringe. Afull
blood count, (Coulter S) platelet count
(Technicon Autocounter) and examination
of a film, were performed on blood anti-
coagulated with EDTA, and the remaining
blood was anticoagulated with a one-tenthEFFECTS OF C. PARVVUM IN MAN
TABLE.-The Changes in Temperature, White Cell Count, Absolute Neutrophil Count,
Absolute Lymphocyte Count, Platelet Count, and f3-thromboglobulin Level before and
after the Infusion of C. parvum 5 mg/M2 Body Surface Area. Mean ] s.d. N - 5
Time (min) Preinfusion
Temperature (°C) 36 4 ± 0 3
21 + 2 77 + 8 137 ± 14 253 ± 12
363 ± 02 368 ± 02 37.9 ± 02 392 ± 03
White cell count
(mm 3)
Neutrophil count
(mm 3)
Lymphocyte count
(mm 3)
Platelet count
( X 103 mm-3)
(-Thromboglobulin
(ng/ml)
5780 ± 1045 5960 ± 2101 2940 ± 921 4040 ± 1370 5160 ± 1617
3910 ± 679 3463 ± 659 1557 ± 797 3380 ± 920 4809 ± 1573
1804 ± 689 1988 ± 1545 1618 ± 1575
241 ± 77
73 ± 65
220 ± 68
120 ± 76
200 ± 63
628 ± 587 222 ± 214
210 ± 59
152 ± 113 169 ± 90
182 ± 79
106 ± 59
X 400 qreinfusion
O200 1
0
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FIG. 1.-Showing the levels of Factor VIII
procoagulant activity ( 0) and
Factor VIII-related antigenicity (N-f),
immediately before and after C. parvum
infusion. Each point represents the mean
values of 5 patients (±s.d.) and the solid
bar represents the period of C. parvum
infusion.
volume of 0dIM trisodium citrate, with and
without the addition of 125I-labelled
human fibrinogen (70,g/4.5 ml whole
blood). Blood was kept on melting ice and
centrifuged at 2800 g for 30 min at +5°C,
within 20 min of sampling. The plasma
was either analysed at once or stored at
-20°C and analysed within 7 days.
Prothrombin time, kaolin/cephalin clot-
tingtimeandthrombintime weremeasured
by standard methods (Hardisty and
Ingram, 1965) fibrinogen by the method
of Burmester et al. (1970) and ethanol gel
according to Godal and Abildgaard (1966).
Plasma fibrinolytic activity was meas-
ured by diluting 0 5 ml plasma containing
a trace of 1251-labelled fibrinogen with
4*5 ml 0.9% NaCl. This was then clotted
with 10 u bovine thrombin, the clots en-
meshed on crushed glass and incubated at
22°C for 60 min. After centrifuging, the
clots were washed with 2 10 ml volumes
of saline and the radioactivity remaining
in the clot was expressed as a percentage
of the total radioactivity in the original
plasma. The mean incorporation of radio-
activity in untreated controls was 62%
(n = 10) and this was regarded as the
baseline fibrinolytic activity for the
patients.
Plasminogen-activator activity was
measured in euglobulin fractions on bovine
fibrin plates (Astrup and Mullertz, 1952).
Other euglobulin fractions prepared
from plasma containing 1251-labelled
fibrinogen were redissolved in an original
volume of barbitone buffer, clotted with
2-5 u of bovine thrombin and incubated
for exactly 60 min at 370C. The remaining
clot was removed and the radioactivity
measured in both clot and supernatant
fluid. The proportion of fibrin lysed at 60
min was then determined.
Plasminogen, oU2-macroglobulin, X1-
antitrypsin and antithrombin III were
measured by radial immunodiffusion on
plates obtained from Hoechst Pharma-
ceuticals (Hoechst House, Kew Bridge,
Brentford, Middlesex). Antiplasmin act-
ivity was measured by an adaptation of
the gel-diffusion method of Lane et al.
(1975).
There was a large fall in the number of
white blood cells, with the virtual dis-
appearance of lymphocytes. There was
also a slight decrease in the platelet count
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FIG. 2.-Fibrinolytic activity before and after
the infusion of C. parvum. (a) Plasma
antiplasmin activity (U U) expressed as
a percentage of pooled normal plasma
antiplasmin activity; plasma fibrinolytic
activity (A - - - A) expressed as a percent-
age of 1251-labelled clot lysis; fibrin(ogen)
degradation products (utg/ml) (0-).
(b) Euglobulin clot lysis (A- - -- ) ex-
pressed as a percentage of lysis of 1251-
labelled euglobulin clots; euglobulin lysis
on bovine fibrin plates (mm2) (0 -*).
Each point represents the mean value of
duplicate results on 5 patients (±s.d.). The
solid bar represents the period of C. parvum
infusion.
and the 3-thromboglobulin levels increased
(Table).
Factor VIII antigen level started to in-
crease 80 min after the start of infusion,
and was more than 31 x the baseline level
in the 250 min samples. There was a
corresponding but smaller increase in
Factor VIII procoagulant activity over
the same period (Fig. 1). Although there
was a slight shortening of the kaolin/ceph-
alin time, the prothrombin time, thrombin
time, fibrinogen concentration, ethanol
gelation, antithrombin III, plasminogen,
ao2-macroglobulin and ocl-antitrypsin con-
centrations did not change.
Both dilute plasma (Fig. 2a) and the
euglobulin fraction (Fig. 2b) showed a
marked increase in fibrinolytic activity at
140 min, but both returned to baseline
values by 250 min after the start of the
infusion. There was a corresponding fall in
antiplasmin activity, and the formation of
high levels of fibrin(ogen) degradation
products.
The in vitro addition of C. parvum to
anticoagulated whole blood, plasma or
euglobulin fraction produced no change in
any of the above tests.
The injection of C. parvum induces a
severe disturbance of homeostasis, which
could be detected shortly after completion
of the infusion. There was a rapid rise in
temperature, often with a period of
hypotension and peripheral vasoconstric-
tion. Fever persists for some hours but the
hypotension and vasoconstriction are
relatively short-lived. With such a severe
physiological disturbance it would be
expected that various cellular and meta-
bolic functions would be altered. Most
attention has been paid to changes in im-
munological function (Gill et at., 1977;
Castro, 1977) but we have demonstrated
marked activation of the fibrinolytic
mechanism, with evidence of plasminogen
activator release as well as increased lysis
offibrin(ogen). This stimulation appears to
be rapidly controlled, for at 250 min most
variables have returned to normal. This
activation of fibrinolysis is presumably
responsible for the large increase in fibrin-
(ogen) degradation products that occurs
at 140 min, even though there was no
detectable change in fibrinogen concentra-
tion.
The changes in Factor VIII levels
appear to follow a completely different
time course. Factor VIII procoagulant
activity and Factor VIII antigen levels
were still rising at 250 min, when fibrino-
lytic activity had returned to normal. It is
not clear from these results whether the
changes in fibrinolysis are directly related
to activation of the clotting system, and
further investigation is required to eluci-
date this point.
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The time lag from the infusion of the
organism to the development of fibrino-
lytic activity probably permits the release
of a substance or substances which then
induce the physiological and haemato-
logical changes. White cells may release
proteases or plasminogen activators (Gans,
1964) and this would result in an increase
in fibrinolytic activity. Furthermore, the
overall response to infusion of C. parvum
is similar to the response seen after endo-
toxin infusion, which can bring about
intravascular clotting, fibrinolytic activa-
tion and endothelial damage (McKay,
1966; Horwitz et al., 1972) although C.
parvum is not a Gram-negative organism
which releases lipopolysaccharide endo-
toxins.
Alterations in coagulation and fibrino-
lysis can produce profound effects on the
growth and spread ofexperimental animal
tumours (Peterson, 1968; Rudenstam,
1968; Brown, 1973) and there is some
evidence that this may be of therapeutic
benefit in man (Hughes, 1964). Activation
of fibrinolysis is associated with a reduc-
tion in the numbers of metastases which
develop from experimental primary tum-
ours (Cliffton and Agostino, 1962). Such a
response might be of therapeutic import-
ance in our own trial, where the primary
tumour has been removed. Repeated
activation of fibrinolytic activity might
prevent implantation of circulating micro-
metastases, whilst alteration in the
haemostatic balance might be the explan-
ation for the beneficial effects that were
seen following daily i.v. injections of C.
parvum in patients with advanced malig-
nancy (Israel et al., 1975). If this were so,
the use of direct fibrinolytic stimulators
might be indicated.
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